July 20th 2022
An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Breast cancer diagnosis during and before pandemic
February 23rd 2022A quality improvement study in JAMA Network Open has found that a significantly lower percentage of patients with breast cancer presented with stage I disease before the COVID-19 pandemic, in 2019, compared to after the start of the pandemic, in 2020.
Read More
Trastuzumab deruxtecan significantly improves PFS, OS in HER2-low metastatic breast cancer
February 22nd 2022Trastuzumab deruxtecan resulted in a statistically significant improvement in progression-free survival and overall survival compared with physician’s choice of chemotherapy in patients with HER2-low unresectable and/or metastatic breast cancer, irrespective of hormone receptor status, meeting the primary and secondary end points of the phase 3 DESTINY-Breast 04 trial.
Read More
Premenopausal ER+ breast cancer recurrence reduced significantly with aromatase inhibitors
December 22nd 2021Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.
Read More
Using a biomarker-driven approach in TNBC
December 21st 2021In using the biomarker approach to the treatment of triple-negative breast cancer, the challenge for the clinician is prioritizing the available treatment options based on the National Comprehensive Cancer Network guidelines for breast cancer, which focus on active agents, preferred single-agent chemotherapy approaches, and doublet options for certain patients at high risk.
Read More
Certain postmenopausal patients with breast cancer can avoid chemotherapy, study shows
December 13th 2021Certain post-menopausal women with HR-positive, HER2-negative breast cancer may be able to only undergo endocrine therapy after surgery – sparing themselves from the chemotherapy side effects.
Read More
The addition of palbociclib to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.
Read More
Novel drug has potential to ‘become new standard of care’ in advanced, ER-positive breast cancer
December 10th 2021The study results — which were presented during the 2021 San Antonio Breast Cancer Symposium — indicated that elacestrant, a selective estrogen receptor degrader (SERD), led to a 30% reduction in the risk of disease progression or death compared with standard of care in the study population.
Read More
FDA grants olaparib priority review in BRCA-mutated HER2-negative high-risk early breast cancer
December 1st 2021Olaparib, which was granted priority review by the FDA, has been shown to improve invasive disease-free survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.
Read More
Lack of health insurance directly reduces cancer screening rates, most recent and long-term
November 8th 2021Disparities across the globe continue to surface as we approach year 2 of the COVID-19 pandemic, especially in health care. As one considers its implications, a research team from the American Cancer Society investigated its potential impact on early cancer detection.
Read More
Dynamic treatment for early-stage triple-negative breast cancer
November 2nd 2021Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.
Read More
CoopERA Results Show Benefits of Giredestrant in ER+/HER2– Early Breast Cancer
October 29th 2021Sara Hurvitz, MD, discusses the coopERA study and how these data, along with findings from other clinical trials, could lead to significant changes in treatment for patients with ER-positive/HER2-negative breast cancer.
Read More
Community-based activity programs benefit underserved breast cancer survivors
October 27th 2021Medically underserved and minority breast cancer survivors experienced improved outcomes and quality of life after participating in community-based physical activity programs, according to recent study results.
Read More
Artificial intelligence can predict risk of recurrence for women with common breast cancer
October 15th 2021They added that this is one of the first proofs of concept illustrating the power of an AI model for identifying parameters associated with relapse that the human brain could not detect.
Read More
FDA approves adjuvant abemaciclib plus endocrine therapy for select HR+ early breast cancer
October 13th 2021The FDA has approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of 20% or higher, as determined by an FDA-approved test.
Read More
Data aid in treatment for vulvovaginal health, sexual function after cancer
October 11th 2021Analyzing the relationship between data from patient self-reports and clinician ratings of vulvovaginal tissue health following cancer can help provide better sexual function treatment for patients, according to a recent study.
Read More
FDA grants trastuzumab deruxtecan breakthrough therapy designation for breast cancer
October 5th 2021The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.
Read More